Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.79 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.50 |
| ▸ | FYN | P06241 | 7/20 | 0.48 |
| ▸ | SRC | P12931 | 7/20 | 0.48 |
| ▸ | VCP | P55072 | 1/20 | 0.46 |
| ▸ | BLK | P51451 | 1/20 | 0.44 |
| ▸ | BMX | P51813 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7120364 | 0.94 | EGFR (0.71) | EGFRERBB2FYNSRCVCP | |
| SCHEMBL7126863 | 0.93 | EGFR (0.69) | EGFRERBB2FYNSRC | |
| SCHEMBL7117688 | 0.90 | EGFR (0.65) | EGFRERBB2FYNSRC | |
| SCHEMBL7122249 | 0.90 | EGFR (0.64) | EGFR | |
| SCHEMBL7122253 | 0.90 | EGFR (0.64) | EGFR | |
| SCHEMBL7127836 | 0.89 | EGFR (0.63) | EGFR | |
| SCHEMBL7127848 | 0.89 | EGFR (0.63) | EGFRERBB2 | |
| SCHEMBL7127832 | 0.89 | EGFR (0.63) | EGFR | |
| SCHEMBL7127852 | 0.89 | EGFR (0.63) | EGFRERBB2 | |
| SCHEMBL7129018 | 0.89 | EGFR (1.00) | EGFRERBB2FYNSRCVCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | claimed |
| US-6153617-A | Irreversible bicyclic inhibitors of tyrosine kinases | WARNER-LAMBERT COMPANY (US) | 2000-11-28 | — | — | US | claimed |
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | disclosed |
| US-6153617-A | Irreversible bicyclic inhibitors of tyrosine kinases | WARNER-LAMBERT COMPANY (US) | 2000-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885ERBB2 1/4885FYN 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.